Autoantibodies against the smaller isoform of glutamic acid decarboxylase (GAD) are markers for Type 1 diabetes. GAD65 autoantibody (GAD65Ab)-positive individuals in the general population are, however, mostly at low risk of developing Type 1 diabetes, suggesting that GAD65Ab phenotypes may be associated with different underlying pathogenic processes. The aim of this study was to test the hypothesis that Type 1 diabetes patients (n ϭ 243; group I), GAD65Ab-positive healthy individuals (n ϭ 28; group II), and healthy first-degree relatives of Type 1 diabetes patients (n ϭ 41; group III) have antibody phenotypes that recognize different GAD65 epitopes. Sera from groups I-III were tested for their binding to GAD65 and GAD67, as well as six different GAD65/67 fusion proteins. Regardless of group, sera reactive to both GAD65 and GAD67 showed broader epitope reactivity than GAD65-specific sera. Furthermore, Type 1 diabetes patients showed a more restricted epitope binding than healthy individuals and first-degree relatives, demonstrating significantly less binding to the N-terminal part of GAD65 and to GAD67. Our analysis demonstrates that the N-terminal part is essential for full antibody binding to GAD65, in particular, to the middle epitope. It is suggested that Type 1 diabetes is associated with restricted GAD65Ab epitope specificity. (J Clin Endocrinol Metab 85: [4671][4672][4673][4674][4675][4676][4677][4678][4679] 2000) 
GAD67, as well as six different GAD65/67 fusion proteins. Regardless of group, sera reactive to both GAD65 and GAD67 showed broader epitope reactivity than GAD65-specific sera. Furthermore, Type 1 diabetes patients showed a more restricted epitope binding than healthy individuals and first-degree relatives, demonstrating significantly less binding to the N-terminal part of GAD65 and to GAD67. Our analysis demonstrates that the N-terminal part is essential for full antibody binding to GAD65, in particular, to the middle epitope. It is suggested that Type 1 diabetes is associated with restricted GAD65Ab epitope specificity. G LUTAMIC ACID DECARBOXYLASE (GAD) catalyzes the synthesis of the neurotransmitter GABA and is encoded by two separate genes, GAD65 and GAD67 (1) (2) (3) . The GAD65 and GAD67 proteins are highly homologous, differing primarily in the amino terminal third of the protein. Although GAD65 is the predominant form in human islets (4) , both molecules can be found in neurons (5, 6) . Autoantibodies directed to the GAD65 isoform (GAD65Ab) are a sensitive and specific marker for Type 1 diabetes, whereas autoantibodies toward GAD67 occur only in a small fraction of Type 1 diabetes patients (7, 8) . GAD65Abs in Type 1 diabetes seem to predominately bind epitopes located in middle (amino acids 240 -435 ϭ M epitope) (9 -11) and carboxyterminal (amino acids 451-570 ϭ C epitope) regions of GAD65 (9 -11) . GAD65Ab can also be found in other autoimmune diseases such as stiff-man syndrome (12, 13) , Graves' disease (14) , autoimmune polyendocrinopathies (15, 16) , in 6 -10% of patients classified with Type 2 or noninsulindependent diabetes (17, 18) , as well as in 1-2% of the healthy population (19) . The latter individuals are at low risk of developing Type 1 diabetes because the prevalence rate is only about 0.3% (20, 21) . Although the autoimmune response in Type 1 diabetes eventually leads to complete destruction of pancreatic ␤ cells (22) , this is not necessarily the case in other GAD65Ab-positive phenotypes, such as healthy adults (23) or first-degree relatives who do not progress to diabetes (24) . It has, therefore, been suggested that the antibody binding to GAD65 in these different GAD65Ab-positive phenotypes differ in epitope specificity (25) . It will be necessary to identify preferred GAD65Ab epitopes in different GAD65Ab-positive phenotypes to better predict and understand the pathogenesis of Type 1 diabetes.
In a previous study (25) , we demonstrated that GAD65Ab in newly diagnosed Type 1 diabetes patients can distinguish between variants of GAD65 (human, mouse, and rat) which differ mainly at the N-terminal part of the molecule. The difference in species-reactivity was more distinct in newly diagnosed teenagers and young adults whose autoantibodies preferred human GAD65 as opposed to mouse or rat GAD65, whereas Type 2 diabetes patients and GAD65Ab-positive healthy individuals showed a broader reactivity. The aim of the present study was to compare the GAD65Ab epitope patterns between three groups of GAD65Ab-positive phenotypes: newly diagnosed Type 1 diabetes patients (group I), healthy adults (group II), and first-degree relatives to Type 1 diabetes patients (group III).
Materials and Methods Subjects
Three groups (I, II, and III) of GAD65Ab-positive individuals and one group of GAD65Ab-negative individuals were employed in this study (Table 1) . Group I consisted of GAD65Ab-positive newly diagnosed Type 1 diabetes patients (n ϭ 243). One subset of this group (n ϭ 125) consisted of 0-to 18-yr-old patients with newly diagnosed Type 1 diabetes. An additional blood sample was obtained for some patients (n ϭ 67) 5 yr after onset of the disease. All of these patients were part of a study conducted at the St. Gö rans Children Hospital (Stockholm, Sweden) and represented 80% of all children diagnosed in Stockholm during 1993-1995. The frequency of GAD65Ab-positive sera in the original group was 76%. The second subset contained 118 15-to 35-yr-old randomly selected newly diagnosed Swedish Type 1 diabetes patients. These patients were registered in 1992-1993 in the Diabetes Incidence Study in Sweden (DISS) and were previously reported to be positive for GAD65Ab (26) . The frequency of GAD65Ab-positive samples in the original patient group was 74%. The serum samples of all diabetes patients in this study were obtained at the clinical diagnosis of diabetes.
Group II represented healthy individuals (n ϭ 28) with a GAD65Ab index above cutoff index (0.05) detected in a population-based screening of 2157 Swedish adults (23) . None of the GAD65Ab-positive healthy individuals developed Type 1 diabetes within 8 yr after the samples were taken (27) .
Group III consisted of 41 healthy GAD65Ab-positive first-degree relatives of Type 1 diabetes patients. These subjects were identified by screening 0-to 93-yr-old first-degree relatives in families with at least two siblings with diabetes to a total of 1170 probands with Type 1 diabetes. The families were identified in the DISS and the Swedish Childhood Diabetes registry. The GAD65Ab-positive first-degree relatives were 7-74 yr of age, and none of them were known to have developed diabetes (in a follow-up time of minimal 2 yr and maximal 12 yr).
We also analyzed sera from 131 randomly selected 15-to 35-yr-old healthy Swedish individuals. These individuals represented the control group in the DISS 92/93 study (25) . Small aliquots of serum samples were kept frozen at Ϫ80 C.
Construction of fusion molecules
The GAD65, GAD67, and chimeric GAD complementary DNA (cDNA) molecules used in the present study are summarized in Table  2 . The constructions of full-length murine GAD65 cDNA clones are described elsewhere (25) . Full-length rat GAD67 cDNA (28) was inserted into pGEM4 (Promega Corp., Madison, WI) and coded pEx12 (29) . Fusion proteins were constructed by substituting GAD65 sequences with corresponding regions of GAD67. The N-fusion molecule consisting of the amino terminal amino acid residues of human GAD65 GAD67 (249 -593) was constructed by introducing a NarI site at position 747 of the GAD67 cDNA clone by PCR. The resulting GAD67 fragment was cloned into the GAD65 cDNA of human using the native NarI site at position 727. To create the NϩM fusion molecule GAD65 GAD67 (426 -593) , a SphI site was introduced at nucleotide position 1279 of the GAD67 cDNA by PCR, and the resulting GAD67 fragment was exchanged with the corresponding fragment of the GAD65 cDNA of human using the native SphI site at position 1266. To create the MϩC fusion molecule GAD67 GAD65 , a NarI site at position 747 of the GAD67 cDNA was introduced by PCR. The corresponding part of the molecule of GAD65 was replaced using a native NarI site in its cDNA. The fusion molecule M was created by introducing a SphI site at nucleotide position 1279 of the GAD67 cDNA by PCR and exchanging the corresponding sequence of the construct GAD67 GAD65 (243-585) (fusion protein MϩC) using a native SphI site at position 1266. The construct GAD65 GAD67 (249 -426) GAD65 (423-585) (fusion protein NϩC) was created by introducing a SphI site at position 1279 of the GAD67 cDNA. The resulting GAD67 fragment was exchanged with the corresponding cDNA fragments of construct GAD65 GAD67 (249 -593) (N-fusion molecule) using the native SphI site. The fusion protein C GAD67 GAD65 was prepared in our laboratory by Dr. Dorota B. Schranz. Each construct was verified by DNA sequence analysis before use. The in vitro translated fusion proteins were assessed by SDS-PAGE and were of the expected molecular weights.
Autoantibody RIA
GAD65Abs were detected by a previously described RIA (29, 30) with recent modifications (25) . Recombinant 35 S-GAD65, IA-2, and fusion proteins were produced by in vitro-coupled transcription/translation with SP6 RNA polymerase and nuclease-treated rabbit reticulocyte lysate (Promega Corp.), as described previously (30) . The in vitro-translated 35 S-GAD65 and fusion proteins were kept at Ϫ80 C and used within 2 weeks of preparation. Equal amounts of labeled antigens were used in the RIA as verified by densitometric analysis by SDS-PAGE.
IA-2Abs were detected as described previously (31) . The upper limit of the normal range was established as the 99th percentile of the levels of 131 healthy control subjects (Table 1 ). Autoantibodies to 125 I-insulin (Amersham Pharmacia Biotech, Buckinghamshire, UK) were measured as described previously in a protein A Sepharose-based immunoprecipiation assay (32) .
Statistical analysis
Results are shown as antibody levels expressed as percent binding of human GAD65, which was set at 100%. Antibody levels were expressed as a relative index to correct for interassay variation using one positive and one negative standard serum described previously (29, 30) . All samples were analyzed in duplicate determinations, and the intra-assay average coefficient of variation was 6.1%. The upper limit of the normal range was established for each GAD65, GAD67, and fusion molecule as the 99th percentile of the levels of the 131 healthy control subjects ( Table  1 ). The Juvenile Diabetes Foundation islet cell autoantibodies standard, which is also GAD65Ab positive (33) , was used as the GAD65Ab-positive standard. A randomly selected control serum from a healthy volunteer was used as negative standard.
The correlation between antibody indices was calculated using the Spearman rank correlation test. The significance of differences between antibody levels was tested with the nonparametric Mann-Whitney U test. A P value of less than 0.05 was considered significant (*, P Ͻ 0.05-0.01; **, P Ͻ 0.001-0.01; and ***, P Ͻ 0.001).
Results

Sera of type 1 diabetes patients bind significantly less to GAD67 and the N-fusion protein compared with healthy individuals and relatives
Most fusion proteins and GAD isoforms were bound equally well by sera from all three GAD65Ab-positive groups (data not shown). However, there were significant differences in the binding to GAD67 and the N terminus of GAD65. GAD67 was bound significantly better by sera from both healthy individuals (group II) (P ϭ 0.0015) and firstdegree relatives (group III) (P ϭ 0.003) compared with Type 1 diabetes patients (group I) (Fig. 1) . We observed that GAD65Ab and GAD67Ab indices do not correlate in any of the study groups (Fig. 2) . The GAD65/67 reactive sera were tested by immunoblotting to determine whether these sera react with denatured GAD65. They failed to recognize GAD65 under these conditions, indicating that the shared epitope is conformational, not linear (data not shown).
We observed significant differences in the binding of GAD65-specific sera and GAD65/67-reactive sera to the different fusion proteins, therefore, observations for GAD65-specific sera and GAD65/67-reactive sera will be reported independently.
The level of binding to the N terminus was higher in healthy individuals (group II) and first-degree relatives (group III) compared with Type 1 diabetes patients (Fig. 3) . This binding pattern was observed both in the GAD65-specific group and in the GAD65/67-reactive group.
Sera reactive to both GAD65 and GAD67 show broader epitope specificity than GAD65-specific sera
In all three GAD65Ab-positive study groups, we observed that GAD65/67-reactive sera reacted better with any of the fusion proteins compared with GAD65-specific sera (Fig. 4,  A-C) . These differences were especially significant in the Type 1 diabetes patients (Fig. 4A) . In sera of group I every tested protein was bound significantly better by GAD65/ 67-reactive sera than by GAD65-specific sera. This binding pattern was less obvious in healthy individuals (Fig. 4B ) and first-degree relatives (Fig. 4C) . In these two groups, significantly preferred binding by the GAD65/67-reactive sera was observed only for the N-, C-, and M-fusion proteins.
Binding to GAD65 is significantly higher than to fusion proteins
GAD65-specific sera. Compared with GAD65, binding to all fusion proteins was significantly reduced in all three GAD65Ab-positive sera groups (Fig. 5, A-C) , with the exceptions of the fusion protein NϩM and mouse GAD65. Whereas GAD65Ab-specific sera of Type 1 diabetes patients (Fig. 5A ) bound human GAD65 significantly better than mouse (P ϭ 0.019), sera of healthy individuals (Fig. 5B) and first-degree relatives (Fig. 5C ) did not differentiate between human and mouse GAD65. Sera of Type 1 diabetes patients showed a significant (P ϭ 0.0001) reduction in binding to the NϩM-fusion protein compared with GAD65. However, in healthy individuals and first-degree relatives no significant difference was observed in the binding to the NϩM fusion protein and GAD65.
GAD65/67-reactive sera. GAD65/67-reactive sera of Type 1 diabetes patients did not differentiate between human and mouse GAD65 (Fig. 6A) , or between GAD65 and the fusion 
FIG. 2. Correlation between GAD65Ab and GAD67Ab levels. Levels of GAD65Ab and GAD67Ab in sera obtained from Type 1 diabetes patients (᭛), healthy individuals (ϫ) and first-degree relatives (⅜)
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proteins NϩM, MϩC, and C (Fig. 6A) . Only the binding of the fusion proteins M (P ϭ 0.011), NϩC (P ϭ 0.0002), and N (P ϭ 0.0001) was significantly reduced compared with GAD65. The binding pattern was similar in group II (Fig. 6B) , where no significant differences in binding were observed, except for the N (P ϭ 0.019) and M-fusion proteins (P ϭ 0.009). Group III sera only differentiated between GAD65 the NϩC fusion protein and the N-fusion protein (P ϭ 0.0085), while binding to GAD65 and the other fusion proteins did not differ (Fig. 6C) .
Antibody reactivity 5 yr after onset of Type 1 diabetes
Blood samples of Type 1 diabetes patients (0-to 18-yr-old subgroup) were obtained at onset of the disease and 5 yr later. When tested for antibody binding to human and mouse GAD65, GAD67, and the N-fusion protein, no significant differences in the binding pattern compared with the onset samples were observed (data not shown).
Serum samples from first-degree relatives who are positive for more than one autoantibody show restricted epitope specificity
Serum samples from the 41 first-degree relatives were also tested for their reactivity to IA-2 and insulin. It was found that 27% (11 of 41) of the samples were positive for GAD65Ab and IA-2Ab and 36% (4 of 11) of these double positive samples tested positive also for insulin autoantibodies. When analyzed for binding to GAD67 and the N-fusion protein, we observed that samples with more than one autoantibody reactivity show restricted epitope specificity. Whereas 13 of 30 (43%) GAD65Ab-positive sera also bound GAD67, only 3 of 11 (27%) sera positive for two autoantibodies were GAD67Ab positive (P ϭ 0.04). Significant differences were also observed in the reactivity to N-fusion protein when 
The N-terminal part increases the antigenicity of the middle epitope
Next, we analyzed the influence of the first 240 amino acids on the binding of both the middle and carboxyterminal region of GAD65. The NϩM fusion protein showed a considerable better binding compared with both N and M fusion proteins (Figs. 5 and 6 ). This binding pattern was observed in all sera groups but was particularly obvious for GAD65-specific Type 1 diabetes patients (Figs. 5a and 6a ) because here the binding to the N-fusion protein was only 1% compared with binding to GAD65. Binding to the M-fusion protein was reduced to 21% (P ϭ 0.0001) compared with GAD65. In contrast, fusion protein NϩM was only reduced to 65% (P ϭ 0.0001) compared with GAD65 and was, hence, bound significantly better than the N-fusion protein (P ϭ 0.0001) or the M-fusion protein (P ϭ 0.0001).
The effect of the N terminus on binding to the C-epitope was less obvious. A significantly better binding of the NϩC fusion protein compared with the N terminus alone was observed only for Type 1 diabetes patients [both GAD65 specific (P ϭ 0.0001) and GAD65/67 reactive (P ϭ 0.0014)] and in GAD65-specific first-degree relatives (P ϭ 0.0002). There were no significant differences in the binding to the C-fusion protein compared with the NϩC fusion protein.
Discussion
In this study, we used GAD65 from two different species, GAD67 and GAD65/67 fusion proteins, to test the hypoth- esis that GAD65Ab diagnostic sensitivity is associated with epitope-specific GAD65Ab. Our approach was to compare three different GAD65Ab-positive phenotypes: Type 1 diabetes patients; GAD65Ab-positive healthy subjects who had not progressed to Type 1 diabetes; and healthy first-degree relatives of Type 1 diabetes patients (who have an average 8-fold risk of developing Type 1 diabetes compared with the healthy population). We report three major findings: 1) GAD65-specific sera of all three groups show a more restricted epitope specificity compared with GAD65/67-reac-
Comparison between GAD65-specific sera and GAD65-67-reactive sera. Type 1 diabetes patients' sera (A), sera of healthy individuals (B), and first-degree relatives (C) were tested for their binding to the different GAD isoforms and fusion proteins. Results of GAD65-specific sera (a) and GAD65/67 reactive sera (b) are reported separately. The antibody level for each sample is expressed as percentage binding in relation to binding to GAD65 (set at 100%). P values are given for each comparison between binding of GAD65-specific sera and GAD65/67 reactive sera to a given protein. Mean values are indicated for each group. tive sera; 2) Type 1 diabetes patients' sera have GAD65Ab specific to the unmodified GAD65 molecule, whereas healthy individuals and first-degree relatives show a broader epitope specificity; and 3) the N-terminal part of GAD65 is critical for antibody recognition of the molecule's middle epitope.
None of the observed findings was age or gender related. No significant differences in the epitope recognition between sera from female or male individuals in the same sera group were observed (data not shown). Because the mean age varies (16 -47 yr) between the sera groups, we tested the possibility that the differences in epitope recognition were age related. However, no significant differences in the binding pattern were observed when different age-classes of the same group were compared (data not shown), suggesting that the observed findings are not age related. GAD65/67-reactive sera of all study groups showed a higher reactivity to all fusion proteins compared with GAD65-specific sera. We, therefore, conclude that antibodies that react with both GAD65 and GAD67 have a broader epitope spectrum compared with GAD65-specific antibodies.
GAD65-specific sera in Type 1 diabetes patients are dependent on the intact molecule of GAD65 as antibodies in group I showed significantly better binding to GAD65 compared with any of the fusion proteins. Furthermore, antibodies in group I are also sensitive to minor amino acid substitutions in the human GAD65 sequence-such as demonstrated by the use of mouse GAD65 and, in part also, GAD67. It should be noted that the differences in amino acid sequences between these molecules are located mainly at the N-terminal end of the molecule. We, therefore, propose that Type 1 diabetes often develops in association with conformational dependent GAD65-specific antibodies directed to a restricted epitope, which is dependent on the amino acid sequence at the N-terminal end of human GAD65. The GAD65-specific sera identified in the healthy individuals and the first-degree relatives, on the other hand, showed broader epitope specificity. The latter sera recognized fusion proteins and could not differentiate between human and mouse GAD65. We showed that the binding to GAD67 and to the N-terminal epitope of GAD65 was significantly lower in Type 1 diabetes patients than in healthy individuals and in first-degree relatives. Furthermore, we compared binding to human and mouse GAD65, GAD67, and the N-fusion protein between serum samples taken at onset of Type 1 diabetes and 5 yr later. Because no differences in the binding pattern were observed, we conclude that the observed epitope specificities tend to remain constant over time. Our findings are in concordance with previous studies that failed to identify epitopes for Type 1 diabetes patients' sera located at the N terminus of GAD65 (9, 10, 34) . Significantly higher C-terminal GAD65Ab indices in Type 1 diabetes patients than in healthy control children were reported previously (34). We did not observe such a binding pattern in the present study. However, the sera of the two studies differ considerably. Whereas the 28 healthy individuals in our study were adults (age range, 40 -60 yr), Falorni et al. (34) studied sera from nine children with a maximal age of 14 yr. It is possible that the reactivity to the C terminus increases with time, although we did not observe any age-related change in the binding pattern to the C terminus. In a recent study of 29 GAD65Ab-positive children to parents with Type 1 diabetes the middle epitope of GAD65 was proposed as the initiating region as sera of 28 of 29 of the children reacted with this region (35) . Their findings in healthy GAD65Ab-positive children that 36% of their GAD65Ab-specific sera reacted with the N-terminal part and 27% of the sera were GAD65/67 cross-reacting support our data in GAD65Ab-positive healthy individuals and first-degree relatives.
Although the N-terminal part does not seem to carry any epitope for GAD65-specific Type 1 diabetes patients, this part of the molecule significantly enhances the binding to the M-fusion protein in this group. Similar trends were observed in the other sera groups, emphasizing the importance of the N terminus. These results cannot be explained by a possible concealment of the middle region in this fusion protein because polyclonal antibodies raised to this region showed exceptionally good binding to this molecule (data not shown).
Our data confirm reports (11, 36) that Type 1 diabetes patients recognize highly conformation-dependent epitopes. We also show that the GAD65Ab epitope reactivity is different in Type 1 diabetes than in nondiabetic GAD65Ab-positive individuals (healthy individuals and first-degree relatives to Type 1 diabetes patients). Our laboratory has demonstrated already (25) that antibodies in Type 1 diabetes patients recognize more specific epitopes because they clearly differentiate between human and rodent GAD65, whereas this is not the case in healthy individuals or firstdegree relatives (in this study). Of note, samples of GAD65Ab-positive first-degree relatives that bind also to IA-2 showed a restricted epitope specificity compared with samples that bound to GAD65 only. Long-term follow-up of these individuals will be necessary to fully delineate the relationship of this antibody profile to diabetes risk. Furthermore, it will be of importance to investigate whether progression to Type 1 diabetes is accompanied by a reduction of recognized epitopes. These results might have major significance in the study of GAD65Ab in the evolution of Type 1 diabetes and in the prediction of the disease.
